This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Evidence-Based Long-Term Treatment of Bipolar II Disorder

Trisha Suppes, MD, PhD, and Ellen B. Dennehy, PhD

Published: October 1, 2002

Article Abstract

Bipolar II disorder is a distinct, lifelong mental illness that affects at least 1.5 million people in theUnited States, is associated with a high incidence of comorbidity, and ends with completed suicide in10% to 15% of diagnosed individuals. Bipolar II disorder is characterized by at least 1 major depressiveepisode with 1 or more hypomanic episodes, as opposed to manic or mixed episodes. While it isexpected that there may be similarities in approaches to managing patients with bipolar I and bipolarII disorders, data suggest differential patient responses to pharmacologic treatments, supporting theneed for research specifically in patients with bipolar II disorder. Despite the prevalence and severityof the disorder, a well-developed scientific database informing long-term treatment choices forbipolar II disorder as an illness differing from bipolar I disorder and major depressive disorder isvirtually absent. A review of the limited and sometimes contradictory information stresses that moreresearch is needed into prophylactic and maintenance treatment of bipolar II disorder.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: Bipolar Disorder

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...